{"disease":{"id":"intra-abdominal-infections","name":"Intra-abdominal infections","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"zavicefta-ceftazidime-avibactam","indication_name":"Complicated intra-abdominal infections (cIAI) caused by certain susceptible bacteria.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavicefta, Ceftazidime-Avibactam","generic_name":"zavicefta-ceftazidime-avibactam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall synthesis","drug_class":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","quality_score":55,"revenue":"638","mechanism":""},{"drug_id":"cefoxitin-sodium","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1200962","indication_name":"Complicated Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"relebactam","indication_name":"Complicated Intra-abdominal Infections (cIAI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"ceftazidime","indication_name":"Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ampicillin-sodium","indication_name":"Intra-Abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AMPICILLIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"piperacillin-and-tazobactam","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piperacillin And Tazobactam","generic_name":"Piperacillin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall; beta-lactamase enzyme","drug_class":"Penicillin-class antibacterial with beta-lactamase inhibitor","quality_score":64,"revenue":null,"mechanism":"Piperacillin and tazobactam is an antibacterial drug combining a penicillin with a beta-lactamase inhibitor."},{"drug_id":"cefoxitin","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Escherichia coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Citrobacter freundii","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterobacter cloacae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Klebsiella oxytoca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterococcus faecalis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterococcus faecium","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."}],"pipeline":[],"offLabel":[],"totalMarketed":17,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04094818","title":"TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis","phase":"","overall_status":"COMPLETED","enrollment_count":1441,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT03678298","title":"Italian Register for the Study of Complicated Intra-Abdominal Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"World Society of Emergency Surgery","has_results":false},{"nct_id":"NCT06633718","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":786,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06828874","title":"A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":696,"lead_sponsor_name":"Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd","has_results":false},{"nct_id":"NCT03358576","title":"Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":674,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":true},{"nct_id":"NCT03744741","title":"HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study","phase":"","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT02784704","title":"Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Tetraphase Pharmaceuticals, Inc","has_results":true},{"nct_id":"NCT01069900","title":"Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":458,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT01506271","title":"Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07172451","title":"Gelaspan vs Crystalloid Therapy in Sepsis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":318,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT03830333","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":268,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05487586","title":"Real-World Study of Ceftazidime Avibactam in China","phase":"","overall_status":"TERMINATED","enrollment_count":220,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00752219","title":"Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03997929","title":"Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03544203","title":"Multicentre Observational Study on Community Acquired Intraabdominal Infections Management","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT04612413","title":"A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Enlivex Therapeutics Ltd.","has_results":false},{"nct_id":"NCT03482245","title":"The Role of Circadian Clock Proteins in Innate and Adaptive Immunity","phase":"NA","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT01789905","title":"Tygacil Drug Use Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07268560","title":"Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT06901544","title":"Capillary Leak Index as a Prognostic Indicator for Post-Operative Abdominal Sepsis in Critically Ill Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Ain Shams University","has_results":true},{"nct_id":"NCT06838585","title":"Intra-Abdominal Sepsis and Relationship Between Cumulative Fluid Balance and Serum Sodium and Chloride Levels and In-Hospital Mortality","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Clinical Center of Vojvodina","has_results":false},{"nct_id":"NCT03862378","title":"Prediction of Intra-abdominal Infectious Complication by Drainage Fluid Analysis","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT03061500","title":"Prognostic Value of Proadrenomedullin in Intra-abdominal Sepsis","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Instituto de Investigación Hospital Universitario La Paz","has_results":false},{"nct_id":"NCT02475733","title":"Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07207291","title":"Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Joincare Pharmaceutical Group Industry Co., Ltd","has_results":false},{"nct_id":"NCT02655419","title":"Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06794541","title":"A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tetraphase Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT03265834","title":"CABI: Antibiotic Duration for Complicated Intra-ABdominal Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT05628493","title":"Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Chinese Medical Association","has_results":false},{"nct_id":"NCT03354754","title":"LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04700787","title":"Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":false}],"total":31},"guidelines":[{"drug_id":"zosyn-in-plastic-container","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of postpartum endometritis or pelvic inflammatory disease in adults caused by beta-lactamase producing isolates of Escherichia coli.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"zosyn-in-plastic-container","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of intra-abdominal infections in adults and pediatric patients (2 months of age and older) caused by beta-lactamase producing isolates of Escherichia coli or members of the Bacteroides fragilis group.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"zosyn-in-plastic-container","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of nosocomial pneumonia (moderate to severe) in adults and pediatric patients (2 months of age and older) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"zosyn-in-plastic-container","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of uncomplicated and complicated skin and skin structure infections in adults, including cellulitis, cutaneous abscesses, and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"zosyn-in-plastic-container","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of community-acquired pneumonia (moderate severity only) in adults caused by beta-lactamase producing isolates of Haemophilus influenzae.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"piperacillin-and-tazobactam","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of intra-abdominal infections in adults and pediatric patients (2 months of age and older) caused by beta-lactamase producing isolates of Escherichia coli or members of the Bacteroides fragilis group.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"piperacillin-and-tazobactam","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of nosocomial pneumonia (moderate to severe) in adults and pediatric patients (2 months of age and older) caused by beta-lactamase producing isolates of Staphylococcus aureus and piperacillin and tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"piperacillin-and-tazobactam","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses, and ischemic/diabetic foot infections in adults caused by beta-lactamase producing isolates of Staphylococcus aureus.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"piperacillin-and-tazobactam","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of postpartum endometritis or pelvic inflammatory disease in adults caused by beta-lactamase producing isolates of Escherichia coli.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"piperacillin-and-tazobactam","guideline_body":"FDA label","recommendation":"Piperacillin and tazobactam is indicated for the treatment of community-acquired pneumonia (moderate severity only) in adults caused by beta-lactamase producing isolates of Haemophilus influenzae.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}